We recently reported that omarigliptin (OMG), a potent, selective, DPP4 inhibitor with a half-life that allows weekly dosing, decreased inflammation and insulin resistance without affecting hemoglobin A1c (HbA1c) or body mass index (BMI) in patients with type 2 diabetes, but daily DPP4 inhibitors such as sitagliptin did not change levels of inflammation and insulin resistance [5]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.